{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T21:26:56Z","timestamp":1760909216999,"version":"build-2065373602"},"reference-count":30,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2020,2,28]],"date-time":"2020-02-28T00:00:00Z","timestamp":1582848000000},"content-version":"unspecified","delay-in-days":27,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2020,2,4]]},"published-print":{"date-parts":[[2020,2]]},"abstract":"<jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Metastatic sarcomatoid renal cell carcinoma (sRCC) is an aggressive variant of RCC with generally poor prognosis. Treatment with vascular endothelial growth factor inhibitors or chemotherapy generates only short-lived responses. Recent research has suggested a role for combination checkpoint inhibition as first line treatment for metastatic sRCC. This therapy consists of induction with cytotoxic T-lymphocyte-associated protein 4 inhibitor, ipilimumab, administered with programmed cell death protein 1 (PD-1) inhibitor, nivolumab. After completion of four cycles of combination therapy, single-agent maintenance nivolumab is recommended until progression. Patients who progress on maintenance nivolumab are switched to alternate therapy. Herein, we present a case of a patient with RCC who progressed on maintenance nivolumab who, on retreatment with ipilimumab, demonstrated a significant response In addition, we summarize important findings to support the role of salvage ipilimumab in patients with sRCC.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Case presentation<\/jats:title>\n                  <jats:p>A 46-year-old man presented with flank pain and hematuria, the work up of which noted a left kidney mass for which he underwent nephrectomy and was diagnosed with localized sRCC with 60% sarcomatoid differentiation. Within 3 months of nephrectomy, he presented with recurrent flank pain and was diagnosed with recurrence of disease. He was treated with ipilimumab 1\u2009mg\/kg and nivolumab 3\u2009mg\/kg for four doses and demonstrated a partial response. He was then transitioned to single agent nivolumab maintenance. After 3\u2009months on maintenance therapy, he was noted to have progression of disease. Given prior response to immune check point combination, it was decided to rechallenge the patient with 1\u2009mg\/kg ipilimumab. After two doses of ipilimumab and nivolumab combination therapy, the patient was noted to have a partial response. He maintained a response for an additional 9 months and treatment was eventually discontinued due to grade 3 toxicity and progression.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>This case report demonstrates the utility of retreatment with ipilimumab as a salvage option for patients progressing on maintenance PD-1 inhibitors in metastatic RCC. Further studies are needed to identify predictors of response and toxicity to this approach, as well as the optimal scheduling of ipilimumab with maintenance nivolumab.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/jitc-2020-000584","type":"journal-article","created":{"date-parts":[[2020,2,29]],"date-time":"2020-02-29T04:35:19Z","timestamp":1582950919000},"page":"e000584","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":4,"title":["Salvage ipilimumab associated with a significant response in sarcomatoid renal cell carcinoma"],"prefix":"10.1136","volume":"8","author":[{"given":"Gemlyn","family":"George","sequence":"first","affiliation":[{"name":"Department of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI 53226, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Schmidt","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI 53226, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Parag","family":"Tolat","sequence":"additional","affiliation":[{"name":"Department of Radiology, Medical College of Wisconsin, Milwaukee, WI 53226, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mathew","family":"Riese","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI 53226, USA"},{"name":"Blood Research Institute, Versiti Blood Center of Wisconsin, Milwaukee, WI 53213, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deepak","family":"Kilari","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI 53226, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2020,2,28]]},"reference":[{"key":"2025100301535329000_8.1.e000584.1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21442"},{"key":"2025100301535329000_8.1.e000584.2","doi-asserted-by":"publisher","DOI":"10.1097\/00000478-200404000-00002"},{"key":"2025100301535329000_8.1.e000584.3","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2011-0227"},{"key":"2025100301535329000_8.1.e000584.4","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-011-9829-8"},{"key":"2025100301535329000_8.1.e000584.5","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2015.33.7_suppl.408","article-title":"A phase II trial of sunitinib and gemcitabine in sarcomatoid and\/or poor-risk patients with metastatic renal cell carcinoma","volume":"33","author":"McKay","year":"2015","journal-title":"JCO"},{"key":"2025100301535329000_8.1.e000584.6","doi-asserted-by":"crossref","first-page":"e897","DOI":"10.1016\/j.clgc.2017.05.018","article-title":"Immune check point inhibition in Sarcomatoid renal cell carcinoma: a new treatment paradigm","volume":"15","author":"Raychaudhuri","year":"2017","journal-title":"Clin Genitourin Cancer"},{"key":"2025100301535329000_8.1.e000584.7","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-15-0150"},{"key":"2025100301535329000_8.1.e000584.8","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/j.celrep.2017.04.031","article-title":"Interferon receptor signaling pathways regulating PD-L1 and PD-L2 expression","volume":"19","author":"Garcia-Diaz","year":"2017","journal-title":"Cell Rep"},{"key":"2025100301535329000_8.1.e000584.9","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.36.15_suppl.4583","article-title":"Outcomes of patients (PTS) with metastatic renal cell carcinoma (mRCC) and sarcomatoid dedifferentiation (sRCC) after treatment with immune checkpoint inhibitors (ICI): a single-institution retrospective study","volume":"36","author":"Ross","year":"2018","journal-title":"JCO"},{"key":"2025100301535329000_8.1.e000584.10","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2019.37.7_suppl.548","article-title":"Results of a phase II study of atezolizumab and bevacizumab in non-clear cell renal cell carcinoma (nccRCC) and clear cell renal cell carcinoma with sarcomatoid differentiation (sccRCC)","volume":"37","author":"McKay","year":"2019","journal-title":"JCO"},{"key":"2025100301535329000_8.1.e000584.11","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2019.37.15_suppl.4513","article-title":"CheckMate 214 post-hoc analyses of nivolumab plus ipilimumab or sunitinib in IMDC intermediate\/poor-risk patients with previously untreated advanced renal cell carcinoma with sarcomatoid features","volume":"37","author":"McDermott","year":"2019","journal-title":"JCO"},{"key":"2025100301535329000_8.1.e000584.12","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-05-4303"},{"key":"2025100301535329000_8.1.e000584.13","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2013.09.041"},{"key":"2025100301535329000_8.1.e000584.14","doi-asserted-by":"publisher","DOI":"10.1097\/PPO.0b013e3182a102d1"},{"key":"2025100301535329000_8.1.e000584.15","doi-asserted-by":"publisher","DOI":"10.1038\/ng.2323"},{"key":"2025100301535329000_8.1.e000584.16","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(12)70584-3"},{"key":"2025100301535329000_8.1.e000584.17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1712126"},{"key":"2025100301535329000_8.1.e000584.18","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-18-0367"},{"key":"2025100301535329000_8.1.e000584.19","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20130579"},{"key":"2025100301535329000_8.1.e000584.20","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2009.06.036"},{"key":"2025100301535329000_8.1.e000584.21","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2012-0483"},{"key":"2025100301535329000_8.1.e000584.22","doi-asserted-by":"crossref","first-page":"3851","DOI":"10.1200\/JCO.2016.72.1985","article-title":"Safety and efficacy of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma: the CheckMate 016 study","volume":"35","author":"Hammers","year":"2017","journal-title":"J Clin Oncol"},{"key":"2025100301535329000_8.1.e000584.23","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2017.35.15_suppl.e21009","article-title":"Salvage combination ipilimumab and nivolumab after failure of prior checkpoint inhibitor therapy in patients with advanced melanoma","volume":"35","author":"Gaughan","year":"2017","journal-title":"JCO"},{"key":"2025100301535329000_8.1.e000584.24","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2019.37.7_suppl.669","article-title":"Ipilimumab plus nivolumab (Ipi\/Nivo) as salvage therapy in patients with immunotherapy (IO)-refractory metastatic renal cell carcinoma (mRCC)","volume":"37","author":"Gul","year":"2019","journal-title":"JCO"},{"key":"2025100301535329000_8.1.e000584.25","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.ejca.2017.01.009","article-title":"Ipilimumab alone or in combination with nivolumab after progression on anti-PD-1 therapy in advanced melanoma","volume":"75","author":"Zimmer","year":"2017","journal-title":"Eur J Cancer"},{"key":"2025100301535329000_8.1.e000584.26","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19870915)60:6<1313::AID-CNCR2820600625>3.0.CO;2-1"},{"key":"2025100301535329000_8.1.e000584.27","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(05)65384-0"},{"key":"2025100301535329000_8.1.e000584.28","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(05)64551-X"},{"key":"2025100301535329000_8.1.e000584.29","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.18.0000"},{"key":"2025100301535329000_8.1.e000584.30","doi-asserted-by":"crossref","first-page":"e79","DOI":"10.1016\/j.clgc.2014.08.011","article-title":"Outcome of patients with metastatic sarcomatoid renal cell carcinoma: results from the International metastatic renal cell carcinoma database Consortium","volume":"13","author":"Kyriakopoulos","year":"2015","journal-title":"Clin Genitourin Cancer"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2020-000584","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T08:53:59Z","timestamp":1759481639000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2020-000584"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,2,28]]},"published-print":{"date-parts":[[2020,2]]}},"alternative-id":["10.1136\/jitc-2020-000584"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2020-000584","relation":{},"ISSN":["2051-1426"],"issn-type":[{"type":"electronic","value":"2051-1426"}],"subject":[],"published":{"date-parts":[[2020,2]]}}}